NCT00280995View on ClinicalTrials.gov

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

August 31, 2007

Conditions
Hypercholesterolemia, Familial
Interventions
DRUG

ISIS 301012

100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

DRUG

ISIS 301012

200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

DRUG

ISIS 301012

300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85

DRUG

ISIS 301012

50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

Trial Locations (6)

10021

New York

27103

Winston-Salem

45229

Cincinnati

60610

Chicago

77030

Houston

1105 AZ

Amsterdam

Sponsors
All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Kastle Therapeutics, LLC

INDUSTRY